InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.069 0.003 (4.55%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Change of Director's Interest Notice - LR 9 Jun 2022 4:43PM $0.150 $0.069 fallen by 54%
$37 Notice Under Section 708A 8 Jun 2022 5:48PM $0.160 $0.069 fallen by 56.88%
$37 Application for quotation of securities - IMU 8 Jun 2022 5:43PM $0.160 $0.069 fallen by 56.88%
$37 IMUGENE APPOINTS DR YANGHEE WOO TO SCIENTIFIC ADVISORY BOARD 1 Jun 2022 9:37AM $0.195 $0.069 fallen by 64.62%
$37 IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022 31 May 2022 10:15AM $0.195 $0.069 fallen by 64.62%
$37 IMUGENE ANNOUNCES PUBLICATION OF ASCO 2022 PD1-VAXX ABSTRACT 27 May 2022 1:01PM $0.185 $0.069 fallen by 62.70%
$37 Letter to Shareholders 23 May 2022 8:37AM $0.200 $0.069 fallen by 65.50%
$37 IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL 18 May 2022 8:22AM $0.165 $0.069 fallen by 58.18%
$37 IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON 10 May 2022 8:31AM $0.160 $0.069 fallen by 56.88%
$37 Response to ASX Query 9 May 2022 2:02PM $0.170 $0.069 fallen by 59.41%
$37 Clarification Announcement 3 May 2022 1:02PM $0.190 $0.069 fallen by 63.68%
$37 Pause in Trading 3 May 2022 10:01AM $0.190 $0.069 fallen by 63.68%
$37 Termination of Supply Agreement 2 May 2022 12:37PM $0.210 $0.069 fallen by 67.14%
$37 Application for quotation of securities - IMU 29 Apr 2022 2:44PM $0.220 $0.069 fallen by 68.64%
$37 Quarterly Activities/Appendix 4C Cash Flow Report 22 Apr 2022 2:23PM $0.225 $0.069 fallen by 69.33%
$37 First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc 13 Apr 2022 9:29AM $0.210 $0.069 fallen by 67.14%
$37 Release of Securities from Escrow 12 Apr 2022 10:35AM $0.225 $0.069 fallen by 69.33%
$37 Application for quotation of securities - IMU 1 Apr 2022 11:53AM $0.253 $0.069 fallen by 72.67%
$37 Dose Escalation in Phase 1 Clinical Trial of CHECKvacc 24 Mar 2022 9:15AM $0.285 $0.069 fallen by 75.79%
$37 Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia 23 Mar 2022 9:54AM $0.260 $0.069 fallen by 73.46%
$37 Investor webinar Imugene & Merck collaboration 15 Mar 2022 9:13AM $0.250 $0.069 fallen by 72.40%
$37 Imugene HER-Vaxx Clinical Trial Collaboration with Merck 15 Mar 2022 8:28AM $0.250 $0.069 fallen by 72.40%
$37 Application for quotation of securities - IMU 4 Mar 2022 5:49PM $0.245 $0.069 fallen by 71.84%
$37 Half Yearly Report and Accounts 28 Feb 2022 10:07AM $0.240 $0.069 fallen by 71.25%
$37 Science Series CHECKvacc 23 Feb 2022 9:17AM $0.255 $0.069 fallen by 72.94%

451 - 475 of 1199 results

Page 19 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.